Literature DB >> 24503272

Safety of Japanese encephalitis live attenuated vaccination in post-marketing surveillance in Guangdong, China, 2005-2012.

Yu Liu1, Hualiang Lin2, Qi Zhu1, Chenggang Wu1, Zhanjie Zhao1, Huizhen Zheng3.   

Abstract

We reviewed the adverse events following immunization of live attenuated Japanese encephalitis vaccine in Guangdong Province, China. During the period of 2005-2012, 23 million doses of live attenuated Japanese encephalitis vaccine were used and 1426 adverse events were reported (61.24 per million doses); of which, 570 (40%) were classified as allergic reactions (24.48 per million doses), 31 (2%) were neurologic events (1.33 per million doses), and 36 (2.5%) were diagnosed as serious adverse events (1.55 per million doses). This study suggests that the JEV-L has a reasonable safety profile, most adverse events are relatively mild, with relatively rare neurologic events being observed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse event following immunization; Japanese encephalitis; Live attenuated vaccine; Safety

Mesh:

Substances:

Year:  2014        PMID: 24503272     DOI: 10.1016/j.vaccine.2013.11.107

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.

Authors:  Xing Li; Shu-Juan Ma; Xie Liu; Li-Na Jiang; Jun-Hua Zhou; Yi-Quan Xiong; Hong Ding; Qing Chen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.

Authors:  Amy Sarah Ginsburg; Ankita Meghani; Scott B Halstead; Mansour Yaich
Journal:  Hum Vaccin Immunother       Date:  2017-08-25       Impact factor: 3.452

Review 3.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

4.  An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.

Authors:  Susan L Hills; Sann Chan Soeung; Svay Sarath; Chheng Morn; Cheam Dara; Marc Fischer; Michael C Thigpen
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

5.  Immunogenicity & safety of a single dose of live-attenuated Japanese encephalitis vaccine SA 14-14-2 in adults.

Authors:  Siraj Ahmed Khan; Sanjeeb Kakati; Prafulla Dutta; Purvita Chowdhury; Jani Borah; Rashmee Topno; Santoshkumar M Jadhav; Pradyumna K Mohapatra; Jagadish Mahanta; Mohan D Gupte
Journal:  Indian J Med Res       Date:  2016-12       Impact factor: 2.375

6.  Safety of Japanese encephalitis vaccines.

Authors:  Ya-Li Hu; Ping-Ing Lee
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

7.  The future of Japanese encephalitis vaccination: expert recommendations for achieving and maintaining optimal JE control.

Authors:  Kirsten S Vannice; Susan L Hills; Lauren M Schwartz; Alan D Barrett; James Heffelfinger; Joachim Hombach; G William Letson; Tom Solomon; Anthony A Marfin
Journal:  NPJ Vaccines       Date:  2021-06-15       Impact factor: 7.344

8.  Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis.

Authors:  Dan He; Han Zhang; Jun Xiao; Xiaofan Zhang; Minjie Xie; Dengji Pan; Minghuan Wang; Xiang Luo; Bitao Bu; Min Zhang; Wei Wang
Journal:  Ann Neurol       Date:  2018-09       Impact factor: 10.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.